Author: CRST

Building a Visual Performance Clinic

Cataract surgery is an exceptional procedure.
Surgeons can correct distance vision, near
vision, and astigmatism with one operation,
and patients often come out of surgery with
only a minimal need—or none at all—for reading glasses.
Altho…

5 Questions With David J. Tanzer MD

How did your career in medicine
lead you to become a refractive surgeon
in the military?

My father served for 20 years as a US
Marine Corps fighter pilot, and I grew up
with a strong desire to experience military
aviation. After c…

Why LASIK Will Become a Rite of Passage

For young people today, the idea of treating refractive
errors with LASIK is a familiar and wellestablished
one. Having grown up hearing about
LASIK and possibly witnessing their parents’ experience
with the procedure, this generation has ne…

5 Questions With David W. Shoemaker, MD

h3What inspired you to found the
Center For Sight?/h3

The inspiration behind the founding of
the Center For Sight is best captured by the
practice’s mission statement, which is to
bring clear vision to life through caring and
trustin…

Two Acquisitions Announced

Alcon Laboratories, Inc., acquired the ophthalmic division
of SensoMotoric Instruments, according to a company
news release. The acquisition provides Alcon with
ocular surgical guidance technology for use in cataract
surgery, such as real-time eye trac…

InSite Vision Completes Phase 3 Clinical Study of BromSite

The final patient has completed dosing and evaluation
in InSite Vision’s phase 3 clinical trial of BromSite (ISV-
303) for the reduction of pain and inflammation after
cataract surgery. BromSite combines a low dose (0.075%)
of the agent bromfenac with InSite Vision’s DuraSite
drug-delivery technology. Top-line data…

Allergan to Buy MAP Pharmaceuticals for $958 Million

Allergan, Inc., has agreed to pay nearly $1 billion to
acquire MAP Pharmaceuticals, a biopharmaceutical company
focused on developing and commercializing new
therapies in neurology, the two companies announced in
a news release. The purchase price of $25 a share in cash
is a 60% premium over MAP’s closing price of $1…